Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply

S Bonovas^{1

2}, T Lytras³, G Nikolopoulos⁴, L Peyrin-Biroulet⁵, S Danese^{1

2}

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
² IBD Center, Humanitas Clinical and Research Center, Milan, Italy.
³ Hellenic Center for Disease Control and Prevention, Athens, Greece.
⁴ Medical School, University of Cyprus, Nicosia, Cyprus.
⁵ Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.

Editorial

S Bonovas et al. Aliment Pharmacol Ther. 2018 Feb.

. 2018 Feb;47(4):540-541.

doi: 10.1111/apt.14486.

S Bonovas^{1

2}, T Lytras³, G Nikolopoulos⁴, L Peyrin-Biroulet⁵, S Danese^{1

2}

¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
² IBD Center, Humanitas Clinical and Research Center, Milan, Italy.
³ Hellenic Center for Disease Control and Prevention, Athens, Greece.
⁴ Medical School, University of Cyprus, Nicosia, Cyprus.
⁵ Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.

No abstract available

Comment on

Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Bonovas S, et al. Aliment Pharmacol Ther. 2018 Feb;47(4):454-465. doi: 10.1111/apt.14449. Epub 2017 Dec 4. Aliment Pharmacol Ther. 2018. PMID: 29205421
Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
Tsai HH. Tsai HH. Aliment Pharmacol Ther. 2018 Feb;47(4):539-540. doi: 10.1111/apt.14480. Aliment Pharmacol Ther. 2018. PMID: 29341281 No abstract available.